Dermatology Daily Update: 01/20/2024
Seborrheic Dermatitis
A phase 3 randomized, double-blinded, vehicle-controlled study investigated the effect of roflumilast foam 0.3% in patients with seborrheic dermatitis (1). The study found that 79.5% of roflumilast-treated patients met the primary endpoint of Investigator Global Assessment (IGA) Success at week 8, compared to 58.0% in the vehicle group. Significant differences in IGA Success also favored roflumilast at week 2 and week 4. The treatment was well-tolerated with a low rate of adverse events.
Reference
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024 Jan 20:S0190-9622(24)00107-5. doi: 10.1016/j.jaad.2023.12.065. Epub ahead of print. PMID: 38253129.
Moderate-to-Severe Atopic Dermatitis
A multicenter, randomized, double-blind, placebo-controlled phase 2b trial in China evaluated the efficacy and safety of CM310 in 120 adults with moderate-to-severe atopic dermatitis (1). The study found that CM310 at doses of 150 mg and 300 mg every 2 weeks significantly improved the Eczema Area and Severity Index (EASI-75) response rate compared to placebo (70% and 65% vs. 20%, respectively). CM310 also significantly improved other dermatological scores and was well-tolerated, with similar incidences of treatment-emergent adverse events across all groups.
Reference
Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, Zhang L, Wang J, Zhu X, Zhang F, Tao X, Li Y, Zhang C, Li L, Lu J, Diao Q, Lu Q, Man X, Li F, Xia X, Cheng H, Jia Y, Zhao G, Yan J, Chen B. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J (Engl). 2024 Jan 20;137(2):200-208. doi: 10.1097/CM9.0000000000002747. Epub 2023 Jul 21. PMID: 37482623; PMCID: PMC10798785.